Keyphrases
Adverse Events
9%
Apolipoprotein A-I (ApoA-I)
9%
Cholesterol
9%
Cholesterol Treatment
9%
Coronary Artery Disease
100%
Diabetic Patients
9%
Dose Titration
9%
Elderly Patients
9%
European Guidelines
100%
High Risk
9%
High-density Lipoprotein Cholesterol (HDL-C)
9%
Highly Effective
9%
Hypertensive Diabetic
9%
Hypertensive Patients
9%
LDL Cholesterol Level
100%
LDL-C Level
100%
Lipids
9%
Low-density Lipoprotein Cholesterol (LDL-C)
36%
Low-density Lipoprotein Cholesterol Goal
18%
Low-density Lipoprotein Cholesterol Level
36%
Mean Reduction
9%
Mg Treatment
9%
Simvastatin
100%
Titration
9%
Treatment Duration
9%
Treatment Goals
9%
Triglycerides
18%
United States
100%
Washout Period
9%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
9%
Apolipoprotein A
9%
Diabetes Mellitus
9%
High Density Lipoprotein Cholesterol
9%
Ischemic Heart Disease
100%
Low Density Lipoprotein Cholesterol
100%
Simvastatin
100%
Triacylglycerol
18%
Biochemistry, Genetics and Molecular Biology
Apolipoprotein
9%
Cholesterol Blood Level
9%
Drug Dose Titration
9%
HDL-Cholesterol
9%
Laboratory Test
9%
Lipid
9%
Low Density Lipoprotein Cholesterol Level
100%
Low-Density Lipoprotein
54%
Simvastatin
100%
Triglyceride
18%